Skip to results
Modify your search
NARROW
1-20 of 1874
Image
The potential of endogenous-ADAR in reverting cancer driver mutations. ( A ...
Published: 06 May 2025
Figure 2.
The potential of endogenous-ADAR in reverting cancer driver mutations. ( A ) Basic data information: Representation of the 2010 patients examined in our analysis, sourced from the pan-cancer analysis of whole genomes (PCAWG) project, categorized by their tumor subtypes, total count of identified dri
Image
Targatable key cancer driver mutations. Illustration of six common cancer d...
Published: 06 May 2025
Figure 4.
Targatable key cancer driver mutations. Illustration of six common cancer driver mutations in the TP53 , KRAS , IDH1 , and IDH2 genes, amenable to endogenous-ADAR.
Image
Calculation of the editing impact. The cumulative percentage of cells to un...
Published: 06 May 2025
Figure 3.
Calculation of the editing impact. The cumulative percentage of cells to undergo editing, presented by the therapeutic editing capability and the quantity of targeted variants. ( A ) When editing one driver mutation per cell is adequate. ( B ) When editing two driver mutations per cell is required.
Journal Article
EDITOR'S CHOICE
A systematic evaluation of the therapeutic potential of endogenous-ADAR editors in cancer prevention and treatment
NAR Cancer, Volume 7, Issue 2, June 2025, zcaf016, https://doi.org/10.1093/narcan/zcaf016
Published: 06 May 2025
Image
Distribution of targetable pathogenic germline mutations. ( A ) Distributio...
Published: 06 May 2025
Figure 1.
Distribution of targetable pathogenic germline mutations. ( A ) Distribution of established pathogenic germline mutations, categorized by CPGs: A total of 2820 SNVs linked to hereditary pediatric cancer risk syndromes are presented based on the respective genes. In parentheses: the total count of va
Image
IBL-1 DLBCL is tightly latent but responds to IgG crosslinking by reactivat...
Published: 05 May 2025
Figure 2.
IBL-1 DLBCL is tightly latent but responds to IgG crosslinking by reactivating EBV and completing the lytic cycle. ( A , B ) IBL-1 cells were treated with the indicated reagents for 24 h to induce the EBV lytic cycle, then collected for analysis of ZEBRA + cells via flow cytometry ( A ) or immunos
Image
Tightly latent BCKN-1 DLBCL responds robustly to some lytic triggers but do...
Published: 05 May 2025
Figure 4.
Tightly latent BCKN-1 DLBCL responds robustly to some lytic triggers but does not support the complete lytic cycle. BCKN-1 cells were exposed to the indicated reagents for 48 h followed by flow cytometric analysis for ZEBRA + cells ( A ), immunostaining with the indicated antibodies ( B ), and qPCR
Image
Lytic triggers upregulate TXNIP to activate the inflammasome in DLBCL lines...
Published: 05 May 2025
Figure 6.
Lytic triggers upregulate TXNIP to activate the inflammasome in DLBCL lines. ( A ) VAL, Farage, and BCKN-1 cells were induced with NaB (VAL and Farage) or NaB + TPA (BCKN-1) for 24 h (VAL) or 48 h (Farage and BCKN-1). Following harvest, cells were subjected to RT-qPCR analysis of TXNIP . ( B – D )
Image
The danger sensing NLRP3 inflammasome activates the EBV lytic cycle in DLBC...
Published: 05 May 2025
Figure 7.
The danger sensing NLRP3 inflammasome activates the EBV lytic cycle in DLBCLs. ( A , B ) Farage ( A ) and VAL ( B ) cells were transfected with control siRNA (siCtrl) or siRNA targeting NLRP3 (si NLRP3 #1, #2). After 20 h, cells were treated with NaB (left panel) or AZA (right panel), harvested
Image
The danger sensing UPR activates NLRP3 inflammasome components and the EBV ...
Published: 05 May 2025
Figure 8.
The danger sensing UPR activates NLRP3 inflammasome components and the EBV lytic cycle in DLBCL. ( A and B ) VAL cells were pre-incubated with different concentrations of tunicamycin (TM) or 4μ8C for 2 h and then left untreated or treated with NaB for another 24 h. Cells were analyzed for ZEBRA ex
Journal Article
Leveraging the interconnected unfolded protein response and NLRP3 inflammasome pathways to reactivate Epstein–Barr virus in diffuse large B-cell lymphomas
NAR Cancer, Volume 7, Issue 2, June 2025, zcaf017, https://doi.org/10.1093/narcan/zcaf017
Published: 05 May 2025
Image
VAL DLBCL supports spontaneous EBV lytic reactivation, with EBV differentia...
Published: 05 May 2025
Figure 1.
VAL DLBCL supports spontaneous EBV lytic reactivation, with EBV differentially responsive to known lytic triggers, and completing the lytic cycle in response to sodium butyrate plus TGF-β. ( A , B ) VAL cells were exposed to several lytic stimuli for 24 h, followed by collection and analysis for ZE
Image
Farage DLBCL is tightly latent but responds to several lytic triggers resul...
Published: 05 May 2025
Figure 3.
Farage DLBCL is tightly latent but responds to several lytic triggers resulting in an abortive lytic phase. Farage cells were treated with different reagents for 48 h to induce EBV reactivation followed by flow cytometric analysis for ZEBRA + cells ( A ), immunostaining with the indicated antibodie
Image
Lytic triggers upregulate NLRP3 to activate the inflammasome in DLBCL lines...
Published: 05 May 2025
Figure 5.
Lytic triggers upregulate NLRP3 to activate the inflammasome in DLBCL lines. ( A ) VAL, Farage, and BCKN-1 cells were treated with NaB (VAL and Farage) or NaB + TPA (BCKN-1) for 24 (VAL) or 48 h (Farage and BCKN-1). Cells were harvested and analyzed for NLRP3 expression using RT-qPCR. ( B ) Farage
Image
Lytic cycle activators enhance oncolytic death of DLBCLs in the presence of...
Published: 05 May 2025
Figure 9.
Lytic cycle activators enhance oncolytic death of DLBCLs in the presence of a nucleoside analog. EBV + DBCL lines VAL ( A , D ) and IBL-1 ( B , E ), and EBV − DLBCL line SUDHL6 ( C , F ) cells were incubated with the specified reagents together with/without GCV for 168 h (VAL and SUDHL6) or 96
Journal Article
Synergistic enhancement of PARP inhibition via small molecule UNI66-mediated suppression of BRD4-dependent transcription of RAD51 and CtIP
NAR Cancer, Volume 7, Issue 2, June 2025, zcaf013, https://doi.org/10.1093/narcan/zcaf013
Published: 30 April 2025
Image
UNI66 reduces HR efficiency. ( A ) HR and ( B ) NHEJ reporter cell lines we...
Published: 30 April 2025
Figure 2.
UNI66 reduces HR efficiency. ( A ) HR and ( B ) NHEJ reporter cell lines were transfected with either an empty vector (pCAG) or the I-SceI expression vector (pCAG-I-SceI). Subsequent to a 48 h exposure to 20 μM UNI66, cells were harvested, and the proportion of GFP-positive cells, indicative of HR o
